Artimplant's employees participate warrant program

Artimplant's employees participate warrant program At Artimplant's Annual General Meeting held May 3, 2000, a warrant program was approved for employees and persons tied to the Artimplant Group. The purpose is to increase the possibilities to recruit and retain qualified personnel, and increase the motivation and interest for the company's earnings development. The program includes 512,500 option rights and each right entitles to subscription of one B share at a price of SEK 300. The warrants are to be exercised no later than March 30, 2004. The subscription time includes the period October 1, 2003 until March 30, 2004. The premium for the warrants is calculated according to the so called Black & Scholes model and is set, taking share price fluctuations into consideration, at the time of transfer. If fully exercised the warrant program will provide the company with proceeds of SEK 154 million and have a dilutionary effect of 5,5% for the capital and 2,8% for the votes. All employees and persons tied to the Artimplant Group have been offered to participate in the warrant program whereof approximately 75 per cent have chosen to subscribe. Of persons in management position or with specialist competence, 28 of 30 have chosen to subscribe. In total 242,600 rights have been subscribed. For further information, please contact: Lars-Erik Nygren, CFO tel: +46 - 31 - 746 56 00 Kari Odhnoff, Investor Relations tel: +46 - 708 - 63 93 41 www.artimplant.se Artimplant is a biomaterial company focused on unmet needs in the field of orthopedic surgery. Artimplant's business concept is to develop, manufacture and market biodegradable implants that provide the injured tissue with temporary relief and support the body's natural healing processes. The vision is to become world-leading within biologically degradable implants that stimulate self-healing and recreate an active life. Artimplant has developed and patented a number of biodegradable ligament implants currently undergoing clinical studies. Early observations from a pilot study using Artimplant's anterior crutiate ligamnet (ACL) implant show subjevtive as well as objective stability in the knee and the technique enables relatively early rehabilitation. A ruptured ACL in the knee is one of the most frequent ligament injuries and often leads to lifelong detrimental effects for the injured, and substantial costs to society. The market potential for Artimplant's ongoing development projects amounts to approximately SEK 30 bn. Furthermore, the market potential for Artimplant's carrier technology is estimated at more than SEK 50 bn. Artimplant's goal is to have at least one product certified year 2000. As part of Artimplant's market strategy Gothenburg Medical Center (GMC) was acquired with the purpose of establishing Swedish headquarters for Artimplant Academy - a forum for advanced clinical research, application and education within orthopedic surgery. Artimplant is listed on the OM Stockholm Exchange O-list. ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/07/17/20000717BIT00350/bit0001.doc http://www.bit.se/bitonline/2000/07/17/20000717BIT00350/bit0002.pdf